Natick Archives - MedCity News https://medcitynews.com/tag/natick/ Healthcare technology news, life science current events Wed, 09 Aug 2023 18:48:19 +0000 en-US hourly 1 https://wordpress.org/?v=6.3.1 https://medcitynews.com/uploads/2021/03/cropped-mblue-32x32.png Natick Archives - MedCity News https://medcitynews.com/tag/natick/ 32 32 40682243 Newly Public Allurion Aims to Show How Med Tech Can Complement Obesity Drugs https://medcitynews.com/2023/08/weight-loss-obesity-medical-device-ai-software-allurion/ https://medcitynews.com/2023/08/weight-loss-obesity-medical-device-ai-software-allurion/#respond Wed, 02 Aug 2023 22:44:20 +0000 https://medcitynews.com/?p=643899

Allurion Technologies has commercialized a gastric balloon in the form of a pill that patients swallow. But the weight loss platform from the now NYSE-listed company also includes AI-driven software that provides insights about a patient’s progress, technology with the potential for use alongside obesity drugs.

]]> https://medcitynews.com/2023/08/weight-loss-obesity-medical-device-ai-software-allurion/feed/ 0 643899 Weight Loss in a Pill Device Firm Allurion Heads to NYSE via SPAC Merger https://medcitynews.com/2023/02/weight-loss-in-a-pill-device-firm-allurion-heads-to-nyse-via-spac-merger/ https://medcitynews.com/2023/02/weight-loss-in-a-pill-device-firm-allurion-heads-to-nyse-via-spac-merger/#respond Thu, 09 Feb 2023 23:45:13 +0000 https://medcitynews.com/?p=623737

Allurion Technologies has developed a gastric balloon that does not require surgery. The merger deal taking Allurion public comes as the company continues global commercialization of its technology.

]]> https://medcitynews.com/2023/02/weight-loss-in-a-pill-device-firm-allurion-heads-to-nyse-via-spac-merger/feed/ 0 623737 Startup Avenge Bio nabs $45M for novel cell therapy approach to ovarian cancer https://medcitynews.com/2022/01/startup-avenge-bio-nabs-45m-for-novel-cell-therapy-approach-to-ovarian-cancer/ https://medcitynews.com/2022/01/startup-avenge-bio-nabs-45m-for-novel-cell-therapy-approach-to-ovarian-cancer/#respond Sun, 09 Jan 2022 23:28:51 +0000 https://medcitynews.com/?p=564911

The field of biotechs pursuing new interleukin-2 cancer immunotherapies is filled with companies engineering different versions of that signaling protein. Avenge Bio CEO Mike Heffernan said his startup stands apart with a cell therapy that produces human IL-2 that could offer advantages compared to engineered versions of that protein.

]]> https://medcitynews.com/2022/01/startup-avenge-bio-nabs-45m-for-novel-cell-therapy-approach-to-ovarian-cancer/feed/ 0 564911